These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25319658)

  • 41. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
    Gregory MA; Phang TL; Neviani P; Alvarez-Calderon F; Eide CA; O'Hare T; Zaberezhnyy V; Williams RT; Druker BJ; Perrotti D; Degregori J
    Cancer Cell; 2010 Jul; 18(1):74-87. PubMed ID: 20609354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
    Kawano N; Okuda S; Yoshida S; Kugimiya H; Ito M; Horikawa N; Chosa N; Hisakata T; Fukudome T; Sakurai R; Yamashita K; Ueda A; Kanda Y
    Int J Hematol; 2011 Dec; 94(6):561-6. PubMed ID: 22057509
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.
    Albajar M; Gutierrez P; Richard C; Rosa-Garrido M; Gómez-Casares MT; Steegmann JL; León J; Delgado MD
    Cancer Lett; 2008 Nov; 270(2):328-36. PubMed ID: 18635311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Grb10 is involved in BCR-ABL-positive leukemia in mice.
    Illert AL; Albers C; Kreutmair S; Leischner H; Peschel C; Miething C; Duyster J
    Leukemia; 2015 Apr; 29(4):858-68. PubMed ID: 25249015
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
    Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
    Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Chronic myeloid leukemia: up-to-date management].
    Nakayama K; Inokuchi K
    Rinsho Ketsueki; 2014 Jan; 55(1):42-55. PubMed ID: 24492036
    [No Abstract]   [Full Text] [Related]  

  • 47. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
    Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
    Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
    Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
    J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia.
    Inami M; Inokuchi K; Nakayama K; Tamura H; Shimada T; Dan K
    Int J Hematol; 2003 Aug; 78(2):173-5. PubMed ID: 12953816
    [No Abstract]   [Full Text] [Related]  

  • 50. Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?
    Marin D
    J Clin Oncol; 2014 Feb; 32(5):379-84. PubMed ID: 24419129
    [No Abstract]   [Full Text] [Related]  

  • 51. [Treatment of chronic myeloid leukemia in chronic phase].
    Matsumura I
    Rinsho Ketsueki; 2014 Oct; 55(10):1853-9. PubMed ID: 25297749
    [No Abstract]   [Full Text] [Related]  

  • 52. Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line.
    Yang C; Panwar N; Wang Y; Zhang B; Liu M; Toh H; Yoon HS; Tjin SC; Chong PH; Law WC; Chen CK; Yong KT
    Nanoscale; 2016 Apr; 8(17):9405-16. PubMed ID: 27092903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
    Valencia-Serna J; Kucharski C; Chen M; Kc R; Jiang X; Brandwein J; Uludağ H
    J Control Release; 2019 Sep; 310():141-154. PubMed ID: 31430499
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.
    McCann SR; Gately K; Conneally E; Lawler M
    Blood; 2003 Feb; 101(3):1200-1. PubMed ID: 12529295
    [No Abstract]   [Full Text] [Related]  

  • 55. The role of Bcr-Abl in chronic myeloid leukemia and stem cell biology.
    Witte O
    Semin Hematol; 2001 Jul; 38(3 Suppl 8):3-8. PubMed ID: 11526595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Knockdown of Alox5 gene promotes apoptosis of K562/ADM cells].
    Luo Y; Xu M; Gao W; Tao K
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Oct; 33(10):1398-1403. PubMed ID: 29169426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.
    Hussein K; Bock O; Seegers A; Flasshove M; Henneke F; Buesche G; Kreipe HH
    Blood; 2007 May; 109(9):4106-7. PubMed ID: 17449802
    [No Abstract]   [Full Text] [Related]  

  • 58. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
    Kaymaz BT; Günel NS; Ceyhan M; Çetintaş VB; Özel B; Yandım MK; Kıpçak S; Aktan Ç; Gökbulut AA; Baran Y; Can BK
    Tumour Biol; 2015 Sep; 36(10):7915-27. PubMed ID: 25953263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
    Valencia-Serna J; Aliabadi HM; Manfrin A; Mohseni M; Jiang X; Uludag H
    Eur J Pharm Biopharm; 2018 Sep; 130():66-70. PubMed ID: 29913272
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.
    Wang J; Lu L; Kok CH; Saunders VA; Goyne JM; Dang P; Leclercq TM; Hughes TP; White DL
    Haematologica; 2017 May; 102(5):843-853. PubMed ID: 28154092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.